Morning light to improve sleep and reduce inflammation in multiple myeloma patients after stem cell transplant

Who could benefit from this research

What this research studies

This trial builds on prior work showing that morning light can help regulate circadian rhythms and lower inflammation in hospitalized patients. Participants will be randomly assigned to receive morning light exposure in their hospital rooms or a comparison condition, with outcomes including sleep quality, mood, neutropenic fever rates, and levels of inflammatory markers. The study will track these measures across the post-transplant recovery period to see if the light exposure translates into meaningful clinical benefits. The approach is designed to be feasible in hospital settings and could be adopted in standard post-transplant care if successful.

Why it matters

Where this research is happening

• Icahn School of Medicine at Mount Sinai
  New York, United States Active

Researchers

• Principal investigator: Valdimarsdottir, Heiddis — Icahn School of Medicine at Mount Sinai
• Study coordinator: Valdimarsdottir, Heiddis

Related research

Other NIH-funded projects on the same topics.

• Morning light to reset the body clock for multiple myeloma patients having autologous stem cell transplant

  This project uses bright, circadian-friendly morning light in hospital rooms for people with multiple myeloma receiving autologous stem cell transplants to help them sleep better, lower inflammation, and reduce fevers and symptom burden.

  NIH research Icahn School of Medicine at Mount Sinai · New York, United States · NIH-11137688

• Effects of light exposure on sleep and inflammation in multiple myeloma patients after stem cell transplantation

  This study is looking at whether getting morning light can help improve sleep, reduce inflammation, and lower the chances of fever in patients with multiple myeloma who are getting stem cell transplants, so they can feel better during their treatment.

  NIH research Icahn School of Medicine at Mount Sinai · New York, United States · NIH-10876916

• Integrative study of multiple myeloma genetics and disease biology

  A team at Dana-Farber and partners is pursuing a long-term project to understand the genetic and molecular drivers of multiple myeloma and how treatments interact with disease biology.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11535381

• Comparative Modeling to Prevent, Detect Early, and Treat Multiple Myeloma

  A research team will build and compare computer models to understand how multiple myeloma develops, can be detected earlier, and treated more effectively.

  NIH research Washington University · Saint Louis, United States · NIH-11495288

• How LDL Affects Multiple Myeloma: New Pathways to Keep Remission

  A new grant is studying how cholesterol from LDL particles fuels multiple myeloma and how this interaction influences the tumor environment and immune response, with goals to help patients stay in remission.

  NIH research Univ of Arkansas for Med Scis · Little Rock, United States · NIH-11444783

• Therapy-induced senescence and immune activation in multiple myeloma

  A study in people with multiple myeloma will explore how treatment-related senescence in cancer cells may stimulate the immune system and affect cancer return after standard frontline therapy.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11433329

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.